Physician profile
Mark C Johnson
NPI 1013923127
$222,961.29
in general payments reported to CMS, 2019-2025
21 companies · $28K in 2025
The $28K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $49K · 2020: $25K · 2021: $39K · 2022: $55K · 2023: $10K · 2024: $17K · 2025: $28K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $50K · Travel and Lodging: $3,393 · Food and Beverage: $2,025 · Education: $161.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $49,890.94 |
| Travel and Lodging | $3,393.26 |
| Food and Beverage | $2,024.67 |
| Education | $161.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $108,855.57 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $24,245.53 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $23,493.45 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $17,825.94 | 2021-2024 | |
| Biohaven Pharmaceuticals, INC. | $16,057.34 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15,235.43 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $11,912.39 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Biohaven Pharmaceutical Holding Company Ltd. | $3,225.11 | 2022 | |
| Medtronic, INC. | $1,159.91 | 2023-2025 | Minimed 780g |
| Abbott Laboratories | $280.55 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Insulet Corporation | $206.76 | 2019-2024 | Omnipod |
| Janssen Pharmaceuticals, INC | $191.70 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $76.68 | 2019 | |
| Corcept Therapeutics | $65.94 | 2019-2020 | |
| Dexcom, INC. | $34.52 | 2023-2025 | Dexcom G6 Transmitter |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tandem Diabetes Care, INC. | $21.94 | 2019-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Daiichi Sankyo INC. | $17.05 | 2020 | |
| Beta Bionics, INC. | $16.97 | 2024 | Ilet Bionic Pancreas |
| Sequel Med Tech, LLC | $15.43 | 2025 | Twiist |
| Amag Pharmaceuticals, INC. | $11.65 | 2019 | |
| Allergan, INC. | $11.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.